Achievements and Perspectives

Multiphase Pumping: Achievements and Perspectives — Multiphase pumping receive now a widespread acceptance of the oil industry. The paper describes the state of the art performance of the helico-axial technology invented and developed by the Institut francais du petrole (IFP). The size of the installed pumps has considerably increased as the industry gained confidence with the accumulation of field experience, both onshore and offshore. A single pump can rate up to 6 MW to-date, and helico-axial pumps are the largest multiphase pumps manufactured in the world. Further research works are still performed at IFP to improve the helico-axial pump performance but also to develop new applications of multiphase turbomachines: sour gas re-injection in solution, wet gas compressors, two-phase turbines. The paper describes the main axes of works and the methodologies applied for these developments. The most advanced experimental and computational techniques are used: laser Doppler anemometry on the experimental side, two-phase CFD simulation and shape optimisation by neural network and genetic algorithm on the design and calculation side.

[1]  A. Waterhouse,et al.  Analysis of pigmented high-molecular-mass grape phenolics using ion-pair, normal-phase high-performance liquid chromatography. , 2000, Journal of chromatography. A.

[2]  Craig W. Reynolds,et al.  In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. , 1983, Journal of immunology.

[3]  C. Thompson,et al.  CD28 costimulation prevents cell death during primary T cell activation. , 1996, Journal of immunology.

[4]  R. Schofield The relationship between the spleen colony-forming cell and the haemopoietic stem cell. , 1978, Blood cells.

[5]  L. E. Bakken,et al.  Gullfaks Multiphase Booster Project , 1995 .

[6]  A. Friedenstein,et al.  STROMAL CELLS RESPONSIBLE FOR TRANSFERRING THE MICROENVIRONMENT OF THE HEMOPOIETIC TISSUES: Cloning In Vitro and Retransplantation In Vivo , 1974, Transplantation.

[7]  Y. Glories,et al.  Determination of the Composition of Commercial Tannin Extracts by Liquid Secondary Ion Mass Spectrometry (LSIMS) , 1996 .

[8]  M P Arnaudeau DEVELOPMENT OF A TWO-PHASE OIL PUMPING SYSTEM FOR EVACUATING SUBSEA PRODUCTION WITHOUT PROCESSING OVER A LONG DISTANCE: POSEIDON PROJECT , 1988 .

[9]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[10]  S. Casares,et al.  Generation of LAK cells in vitro in patients with acute leukemia. , 1993, Leukemia.

[11]  C. Bieberich,et al.  Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. , 1988, Annual review of immunology.

[12]  J. Tikerpae,et al.  Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. , 1992, Journal of immunology.

[13]  R. Arceci,et al.  Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. , 1996, Blood.

[14]  M. Chien,et al.  Characterization of grape procyanidins using high-performance liquid Chromatography/Mass spectrometry and matrix-assisted laser Desorption/Ionization time-of-flight mass spectrometry. , 2000, Journal of agricultural and food chemistry.

[15]  J. Triffitt,et al.  Adipocytic cells cultured from marrow have osteogenic potential. , 1991, Journal of cell science.

[16]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[17]  H. Heslop,et al.  Adoptive cellular immunotherapy for EBV lymphoproliferative diseases , 1997 .

[18]  A. Tosti,et al.  Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three-loci" HLA-incompatible bone marrow transplantation. , 1996, Blood.

[19]  S. Guyot,et al.  Methods for Determining the Degree of Polymerization of Condensed Tannins: A New 1H-NMR Procedure Applied to Cider Apple Procyanidins , 1999 .

[20]  D. Blaise,et al.  Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. , 1995, Blood.

[21]  M. Herderich,et al.  Characterization of proanthocyanidins in grape seeds using electrospray mass spectrometry. , 2003, Rapid communications in mass spectrometry : RCM.

[22]  Lieping Chen,et al.  Can Co‐stimulated Tumor Immunity be Therapeutically Efficacious? , 1995, Immunological reviews.

[23]  M. Scott,et al.  IN SEARCH OF THE HAEMOPOIETIC STEM CELL , 1995, British journal of haematology.

[24]  J. Glowacki,et al.  Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Greenberg,et al.  Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. , 1997, Blood.

[26]  E. Archimbaud,et al.  Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance , 1991, British journal of haematology.

[27]  L. Chen,et al.  Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors , 1996, The Journal of experimental medicine.

[28]  Craig W. Reynolds,et al.  Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? , 1994, Blood.

[29]  S. Rosenberg,et al.  Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. , 1985, Journal of the National Cancer Institute.

[30]  James M. Wilson,et al.  CD40 Ligand-Dependent T Cell Activation: Requirement of B7-CD28 Signaling Through CD40 , 1996, Science.

[31]  J. Dick,et al.  Differential Maintenance of Primitive Human SCID-Repopulating Cells, Clonogenic Progenitors, and Long-Term Culture-Initiating Cells After Incubation on Human Bone Marrow Stromal Cells , 1997 .

[32]  B. G. Chan,et al.  The conversion of procyanidins and prodelphinidins to cyanidin and delphinidin , 1985 .

[33]  M. Moore,et al.  Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. , 1995, Journal of immunology.

[34]  D. Leavesley,et al.  Potential adhesion mechanisms for localisation of haemopoietic progenitors to bone marrow stroma. , 1994, Leukemia & lymphoma.

[35]  C. Nagel,et al.  Changes in the Anthocyanins, Flavonoids and Hydroxycinnamic Acid Esters during Fermentation and Aging of Merlot and Cabernet Sauvignon , 1979, American Journal of Enology and Viticulture.

[36]  J. Mayordomo,et al.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.

[37]  V. Kováč,et al.  The Effect of Adding Supplementary Quantities of Seeds During Fermentation on the Phenolic Composition of Wines , 1995, American Journal of Enology and Viticulture.

[38]  S. Rosenberg,et al.  Separation and functional studies of the human lymphokine-activated killer cell. , 1987, Cancer research.

[39]  C. Nagel,et al.  High-Pressure Liquid Chromatographic Separation of Anthocyanins of Vitis Vinifera , 1978, American Journal of Enology and Viticulture.

[40]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[41]  P. Musiani,et al.  Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[42]  V. Cheynier,et al.  2D NMR analysis for unambiguous structural elucidation of phenolic compounds formed through reaction between (+)‐catechin and glyoxylic acid , 2002 .

[43]  M. Bourzeix,et al.  Separation and quantitative determination of grape and wine procyanidins by high performance reversed phase liquid chromatography , 1990 .

[44]  J. Gribben,et al.  Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. , 1996, Blood.

[45]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[46]  J. Falkenburg,et al.  Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. , 1995, Blood.

[47]  G. Almeida-Porada,et al.  THE ROLE OF SHEEP STROMA IN HUMAN HAEMOPOIESIS IN THE HUMAN/SHEEP CHIMAERAS , 1996, British journal of haematology.

[48]  J. Ritz,et al.  Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF , 1992, The Journal of experimental medicine.

[49]  V. Cheynier,et al.  Quantitative fractionation of grape proanthocyanidins according to their degree of polymerization. , 1999, Journal of agricultural and food chemistry.

[50]  C. Rooney,et al.  Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro , 1996, Journal of virology.

[51]  S. Guyot,et al.  ESI-MS analysis of polyphenolic oligomers and polymers : New methods for analysing old plant polyphenols , 1997 .

[52]  S. Fosså,et al.  Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. , 1989, European journal of cancer & clinical oncology.

[53]  Yumiko Nakamura,et al.  Analysis of Proanthocyanidins in Grape Seed Extracts, Health Foods and Grape Seed Oils , 2003 .

[54]  G. Hale,et al.  Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. , 1998, Blood.

[55]  J. Miller,et al.  CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. , 1996, Blood.

[56]  N. Romani,et al.  High Level IL-12 Product ion by Murine Dendrit ic Cells : Upregulation via MHC Class II and CD 40 Molecules and Downregulat ion by IL-4 and IL-10 By , 2003 .

[57]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[58]  K. Lucas,et al.  Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts , 1997, Immunological reviews.

[59]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[60]  K. Tamada,et al.  The involvement of transforming growth factor beta in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). , 1995, Cancer research.

[61]  Y. Glories,et al.  Composition and cellular localization of tannins in grape seeds during maturation. , 2003, Journal of agricultural and food chemistry.

[62]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[63]  C. Janeway,et al.  Signals and signs for lymphocyte responses , 1994, Cell.

[64]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[65]  M. Moser,et al.  Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo , 1994, European journal of immunology.

[66]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[67]  M. El Hajem,et al.  Exploration par anémométrie laser Doppler de l'écoulement dans une pompe hélico-axiale , 2001 .

[68]  J. Miller,et al.  Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. , 1994, Blood.

[69]  C. Verfaillie,et al.  Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. , 1989, Blood.

[70]  L. Adorini,et al.  Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. , 1995, Journal of immunology.

[71]  D. Kohn,et al.  Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors. , 1994, Blood.

[72]  D. Valerio,et al.  Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[73]  M. Colonna Immunology: Unmasking the killer's accomplice , 1998, Nature.

[74]  E. Gilboa,et al.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.

[75]  H. Kimura,et al.  A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma , 1997, Cancer.

[76]  P. Simmons,et al.  CD34 expression by stromal precursors in normal human adult bone marrow. , 1991, Blood.

[77]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[78]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[79]  J. Djeu,et al.  Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. , 1994, Blood.

[80]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[81]  T. Kipps,et al.  Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. , 1995, Cellular immunology.

[82]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[83]  Douglas N. Rutledge,et al.  Multivariate statistical analysis of two-dimensional NMR data to differentiate grapevine cultivars and clones , 1996 .

[84]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[85]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[86]  S. Lazarus,et al.  High-performance liquid Chromatography/Mass spectrometry analysis of proanthocyanidins in foods and beverages. , 1999, Journal of agricultural and food chemistry.

[87]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[88]  M. Atkins,et al.  A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Emile Leporcher,et al.  Deployment of Multiphase Pumps on a North Sea Field , 2001 .

[90]  J. Sapis,et al.  Changes and importance of oligomeric procyanidins during maturation of grape seeds , 1985 .

[91]  A. Lea Reversed-phase gradient high-performance liquid chromatography of procyanidins and their oxidation products in ciders and wines, optimised by Snyder's procedures , 1980 .

[92]  D. Niederwieser,et al.  Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. , 1996, Journal of immunological methods.

[93]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[94]  A. Hindenburg,et al.  Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia , 1994 .

[95]  Irina Angelikadi,et al.  Monitoring and controlling the biogas process , 1997 .

[96]  T. Dexter Regulation of hemopoietic cell growth and development: experimental and clinical studies. , 1989, Leukemia.

[97]  D. Porter,et al.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.

[98]  J. Ozols,et al.  Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[99]  A. Keating,et al.  Effect of different promoters on expression of genes introduced into hematopoietic and marrow stromal cells by electroporation. , 1990, Experimental hematology.

[100]  T. Whiteside,et al.  Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. , 1996, Cancer research.

[101]  C. Thompson,et al.  Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? , 1995, Cell.

[102]  V. L. Singleton,et al.  Isolation and Determination of Polymeric Polyphenols in Wines Using Sephadex LH-20 , 1991, American Journal of Enology and Viticulture.

[103]  G. Freeman,et al.  Role of B7-1 in mediating an immune response to myeloid leukemia cells. , 1995, Blood.

[104]  C. Verfaillie,et al.  Expansion and activation of human natural killer cells for autologous therapy. , 1994, Journal of hematotherapy.

[105]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[106]  M. Williamson,et al.  Structure and conformation of the procyanidin B‐2 dimer , 1997 .

[107]  A. Burroughs,et al.  Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. , 1998, Journal of immunology.

[108]  F. Locatelli The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation , 1998, British journal of haematology.

[109]  J. Falkenburg,et al.  Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. , 1997, Human immunology.

[110]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  P. Hokland,et al.  Natural killer cells in peripheral blood after autologous bone marrow transplantation: a combined phenotypic and functional study. , 1995, Natural immunity.

[112]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[113]  W. Seaman,et al.  A natural killer cell receptor specific for a major histocompatibility complex class I molecule , 1994, The Journal of experimental medicine.

[114]  J. Falkenburg,et al.  Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia , 1992, The Journal of experimental medicine.

[115]  R. Steinman,et al.  Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. , 1994, The Journal of clinical investigation.

[116]  A. Waterhouse,et al.  Changes in grape seed polyphenols during fruit ripening. , 2000, Phytochemistry.

[117]  Stephen P. A. Brown,et al.  THE EFFECT OF HUMAN IL‐2‐ACTIVATED NATURAL KILLER AND T CELLS ON GRAFT‐VERSUS‐HOST DISEASE AND GRAFT‐VERSUS‐LEUKEMIA IN SCID MICE BEARING HUMAN LEUKEMIC CELLS , 1995, Transplantation.

[118]  G. Pawelec,et al.  BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. , 1996, Blood.

[119]  A. Lea High performance liquid chromatography of cider procyanidins , 1979 .

[120]  S. Gronthos,et al.  The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro. , 1995, Blood.

[121]  J. de Salis,et al.  Multiphase Pumps for 250,000 bbl/D Field Development , 2001 .

[122]  J. Hansen,et al.  Alloantigen Presenting Function of Normal Human CD34+ Hematopoietic Cells , 1996 .

[123]  J. McKenzie,et al.  HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. , 1997, Blood.

[124]  N. Frahm,et al.  The defined attenuated Listeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long‐lasting immune response against a mouse fibrosarcoma , 1997, European journal of immunology.

[125]  J. Falkenburg,et al.  Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. , 1995, The Journal of clinical investigation.

[126]  E. Leporcher,et al.  Multiphase pumping: The lessons of long-term field testing , 1995 .

[127]  V. L. Singleton,et al.  Isolation and Determination of Polymeric Polyphenols Using Sephadex LH-20 and Analysis of Grape Tissue Extracts , 1990 .

[128]  P. Simmons,et al.  Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1 , 1991 .

[129]  R. Fisher,et al.  Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  E. Lotzová,et al.  Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. , 1987, Leukemia research.

[131]  C. Eaves,et al.  Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. , 1993, Experimental hematology.

[132]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[133]  Irini Angelidaki,et al.  Codigestion of olive oil mill wastewaters with manure, household waste or sewage sludge , 1997 .

[134]  D. Hanahan,et al.  Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. , 1996, The Journal of clinical investigation.

[135]  R. Puri,et al.  In Vivo Proliferation of Adoptively Transferred Tumor‐Infiltrating Lymphocytes in Mice , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[136]  T. Fitzgerald,et al.  Improved hematopoiesis in anemic Sl/Sld mice by splenectomy and therapeutic transplantation of a hematopoietic microenvironment. , 1989, Blood.

[137]  E. Goulmy Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[138]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[139]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[140]  R. Jain,et al.  Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. , 1996, Cancer research.

[141]  R. Elashoff,et al.  Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine , 1992, Annals of surgery.

[142]  A. Nagler,et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. , 1996, Blood.

[143]  M. Colombo,et al.  Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. , 1996, Human gene therapy.

[144]  J. Kennedy,et al.  Analysis of proanthocyanidins by high-performance gel permeation chromatography. , 2003, Journal of chromatography. A.

[145]  V. Calcaterra,et al.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.

[146]  M. Horowitz,et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose , 1993 .

[147]  S. Uchida Condensed tannins scavenge active oxygen free radicals , 1987 .

[148]  A I Caplan,et al.  Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. , 1995, Bone marrow transplantation.

[149]  J. Goldman,et al.  Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.

[150]  R. Levy,et al.  Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma , 1993, Nature.

[151]  J. Goldman,et al.  The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation , 1997, British journal of haematology.

[152]  L. Kanz,et al.  Generation of antigen‐presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients , 1996, European journal of immunology.

[153]  M. Colombo,et al.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo , 1991, The Journal of experimental medicine.

[154]  H. L. Longworth,et al.  Underground Disposal of Acid Gas in Alberta, Canada: Regulatory Concerns and Case Histories , 1996 .

[155]  E. Gilboa,et al.  Induction of antitumor immunity using bone marrow-generated dendritic cells. , 1996, Journal of immunology.

[156]  D. Huhn,et al.  Propagation of large numbers of T cells with natural killer cell markers , 1994, British journal of haematology.

[157]  R. Steinman,et al.  Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells , 1990, The Journal of experimental medicine.

[158]  N. Hensel,et al.  Preferential usage of T cell receptor (TCR) V β by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease , 1997, Bone Marrow Transplantation.

[159]  S. Rosenberg,et al.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes , 1991, The Journal of experimental medicine.

[160]  H. Broxmeyer,et al.  Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. , 1980, Blood.

[161]  A. Sette,et al.  Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.

[162]  S. Singhal,et al.  Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy , 1997, Bone Marrow Transplantation.

[163]  J. Schlom,et al.  Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. , 1997, Journal of immunotherapy.

[164]  R. Goldfarb,et al.  Localization of immune effector cells to tumor metastases. , 1994, Immunology series.

[165]  C. Bordignon,et al.  Peripheral Blood Lymphocytes as Target Cells of Retroviral Vector-Mediated Gene Transfer , 1994 .

[166]  Baoshan Sun,et al.  Separation of Grape and Wine Proanthocyanidins According to Their Degree of Polymerization , 1998 .

[167]  R. Steinman,et al.  Dendritic cells pulsed with protein antigens in vitro can prime antigen- specific, MHC-restricted T cells in situ [published erratum appears in J Exp Med 1990 Oct 1;172(4):1275] , 1990, The Journal of experimental medicine.

[168]  G. Keller,et al.  Generation of purified stromal cell cultures that support lymphoid and myeloid precursors. , 1986, Journal of immunological methods.

[169]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[170]  R. Newman,et al.  Polymeric proanthocyanidins. Stereochemistry, structural units, and molecular weight , 1981 .

[171]  Y. Glories,et al.  Characterisation of oligomeric and polymeric procyanidins from grape seeds by liquid secondary ion mass spectrometry , 1998 .

[172]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[173]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[174]  L. Lanier,et al.  Inhibitory MHC class I receptors on NK cells and T cells. , 1996, Immunology today.

[175]  R. Jain,et al.  Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution. , 1989, Cancer research.

[176]  R. Schwartz,et al.  Models of T Cell Anergy: Is There a Common Molecular Mechanism? , 1996 .

[177]  D. Fitzpatrick,et al.  Isolation and characterization of endothelium-dependent vasorelaxing compounds from grape seeds. , 2000, Journal of agricultural and food chemistry.

[178]  F. Locatelli,et al.  Alloantigen-induced human lymphocytes rendered nonresponsive by a combination of anti-CD80 monoclonal antibodies and cyclosporin-A suppress mixed lymphocyte reaction in vitro. , 1995, Journal of immunology.

[179]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[180]  A. Friedenstein,et al.  THE DEVELOPMENT OF FIBROBLAST COLONIES IN MONOLAYER CULTURES OF GUINEA‐PIG BONE MARROW AND SPLEEN CELLS , 1970, Cell and tissue kinetics.

[181]  J. M. D. Silva,et al.  Catechin and procyanidin composition of seeds from grape cultivars grown in Ontario. , 1997 .

[182]  R. Levy,et al.  Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. , 1990, Journal of immunology.

[183]  A. Waterhouse,et al.  A Comparison of Methods For Quantifying Oligomeric Proanthocyanidins From Grape Seed Extracts , 2000, American Journal of Enology and Viticulture.

[184]  R. Steinman,et al.  The endocytic activity of dendritic cells , 1995, The Journal of experimental medicine.

[185]  K. Dorshkind,et al.  B lymphocyte precursors and myeloid progenitors survive in diffusion chamber cultures but B cell differentiation requires close association with stromal cells. , 1987, Blood.

[186]  R. Motzer,et al.  Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma , 1995, Cancer.

[187]  S. Rosenberg,et al.  Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. , 1987, Journal of immunology.

[188]  B. Bogen,et al.  Clonal deletion of thymocytes as a tumor escape mechanism , 1998, International journal of cancer.

[189]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[190]  P. Reinert,et al.  Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia. , 1995, Bone Marrow Transplantation.

[191]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[192]  M. Caligiuri,et al.  Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. , 1996, Blood.

[193]  R. Foà,et al.  Cytotoxic effectors activated by low‐dose IL‐2 plus IL‐12 lyse IL‐2‐resistant autologous acute myeloid leukaemia blasts , 1998, British journal of haematology.

[194]  A. Harris,et al.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.

[195]  R. Cameron,et al.  Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. , 1988, Cancer research.

[196]  E. Waters,et al.  Quantitative analysis of polymeric procyanidins (Tannins) from grape (Vitis vinifera) seeds by reverse phase high-performance liquid chromatography. , 2001, Journal of agricultural and food chemistry.

[197]  S M Larson,et al.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  A. Toubert,et al.  Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. , 1998, Critical reviews in immunology.

[199]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[200]  Johan,et al.  Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells. , 1995, Blood.

[201]  R. Steinman,et al.  Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses , 1993, The Journal of experimental medicine.

[202]  A. Cheminat,et al.  Procyanidin dimers and trimers from grape seeds , 1991 .

[203]  S Kimbrough,et al.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. , 1998, Blood.

[204]  Celestino Santos-Buelga,et al.  Proanthocyanidins and tannin‐like compounds – nature, occurrence, dietary intake and effects on nutrition and health , 2000 .

[205]  Jean Falcimaigne,et al.  Multiphase Rotodynarnic Pumps Extend their Operating Capabilities , 1994 .

[206]  J. Gribben,et al.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[207]  B. Gabetta,et al.  Characterization of proanthocyanidins from grape seeds. , 2000, Fitoterapia.

[208]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[209]  R. Gale,et al.  Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation. , 1985, The Journal of clinical investigation.

[210]  J. Griffin Hemopoietins in oncology: factoring out myelosuppression. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  D. Niederwieser,et al.  Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the philadelphia translocation and can induce a CML‐specific primary cytotoxic T‐cell response , 1997, Genes, chromosomes & cancer.

[212]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[213]  G. Freeman,et al.  B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. , 1996, Journal of immunology.

[214]  D. Kufe,et al.  Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells , 1997, Nature Medicine.

[215]  M. Rosenzwajg,et al.  Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. , 1996, Blood.

[216]  J. Szer,et al.  Bone marrow stromal function from patients after bone marrow transplantation. , 1995, Bone marrow transplantation.

[217]  J. Mier,et al.  Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. , 1988, Cancer research.

[218]  S. Gerson,et al.  Phenotypic and functional comparison of cultures of marrow‐derived mesenchymal stem cells (MSCs) and stromal cells , 1998, Journal of cellular physiology.

[219]  C. Rinaldo,et al.  HLA-restricted lysis of herpes simplex virus-infected monocytes and macrophages mediated by CD4+ and CD8+ T lymphocytes. , 1989, Journal of immunology.

[220]  M. Colombo,et al.  Interferon γ–independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colony–stimulating Factor , 1998, The Journal of Experimental Medicine.

[221]  F. Prósper,et al.  Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. , 1997, Blood.

[222]  P. Ricciardi-Castagnoli,et al.  Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[223]  S. Gronthos,et al.  The biology and application of human bone marrow stromal cell precursors. , 1996, Journal of hematotherapy.

[224]  K. Kliche,et al.  Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. , 1997, Blood.

[225]  T. Starzl,et al.  Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. , 1997, Transplantation.

[226]  P. Colombat,et al.  Haemopoiesis of transplanted patients with autologous marrows assessed by long‐term marrow culture , 1994, British journal of haematology.

[227]  H. Bear,et al.  Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. , 1992, Cancer research.

[228]  V. Cheynier,et al.  Oligomeric and polymeric procyanidins from grape seeds. , 1994 .

[229]  S. Rosenberg,et al.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. , 1987, Journal of the National Cancer Institute.

[230]  K. Dorshkind,et al.  Pre-B cell generation potentiated by soluble factors from a bone marrow stromal cell line. , 1988, Journal of immunology.

[231]  C. Anasetti,et al.  Expression of CD86 on Human Marrow CD34+ Cells Identifies Immunocompetent Committed Precursors of Macrophages and Dendritic Cells , 1998 .

[232]  S. Rosenberg Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. , 1985, Journal of the National Cancer Institute.

[233]  Jon Arve Svaeren,et al.  Application and Status of New Building Blocks for Subsea Boosting and Processing Systems , 2000 .

[234]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[235]  R. Giavazzi,et al.  Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. , 1995, Human gene therapy.

[236]  T. Nose,et al.  Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme. , 1996, Journal of neurosurgery.

[237]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[238]  S. Perkins,et al.  Hematopoietic microenvironment. Origin, lineage, and transplantability of the stromal cells in long-term bone marrow cultures from chimeric mice. , 1988, The Journal of clinical investigation.